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A sensitive and reproducible method for the identification and
the quantitative determination of bupropion (BUP) and its
major metabolites, hydroxybupropion (OH-BUP) and
threohydrobupropion (T-BUP), was developed in blood and
urine. The three compounds were extracted with a solid-phase
extraction procedure followed by LC–ESI-MS–MS separation
and quantification using decadeuterated lidocaine as internal
standard. BUP and its metabolites were satisfactorily identified by
multiple reactions monitoring detection. The limits of detection
and quantification were determined at 5 and 10 µg/L, respectively,
for each analyte. The intraday and interday coefficients of
variability were lower than 11.9% for BUP and its metabolites.
This method was applied to the forensic case of a 35-year-old male
who died after a suspected ingestion of 30 slow-release tablets of
Zyban. As samplings were performed at least 72 h after the drug
intake, BUP had disappeared from blood, but OH-BUP and T-BUP
were present at the concentrations of 5.8 and 30.4 mg/L,
respectively. In urine, concentrations ranged from 42.9 mg/L for
BUP to 617 mg/L for T-BUP. These results agree with the
hypothesis of a successful suicide attempt.
Introduction
Tobacco use remains one of the major causes of death in the
world. For many years, several European countries have
launched active campaigns against tobacco use. Several nico-
tine substitution products have been proposed to smokers in
order to help them to stop. In 1997, the Food and Drug Ad-
ministration (FDA) approved the use of an antidepressant drug,
bupropion (BUP), to help adult smokers to stop tobacco use (1).
Originally approved for the treatment of depression in 1985,
BUP was removed from International Pharmacopeia one year
later because of the important risk of seizures, mainly identified
in sub-populations with epilepsy or a history of head trauma (2).
Complementary studies showed that, at a lower dose range, the
incidence of seizures was similar to that of other antidepressant
drugs. The product was reintroduced in 1989 with special at-
tention paid to side effects in patients with known epilepsy or suf-
fering from eating disorders (1,2). The daily oral dose, used for
depression as well as smoking cessation, is about 300 mg, ad-
ministered in normal release tablets of 75 or 100mg (depression)
or in sustained release tablets of 150 mg (smoking cessation).
Therapeutic concentrations of BUP in blood when these doses
are used range between 25 and 100 µg/L (3).
BUP is a monocyclic antidepressant, chemically unrelated to
tricyclic, tetracyclic, or other known antidepressant agents.
This drug is structurally similar to amphetamine and diethyl-
propion, an anorexigenic drug. Its therapeutic efficacy is, how-
ever, comparable to that of classical antidepressants. In fact,
bupropion is a dual dopaminergic and noradrenergic reuptake
inhibitor, presenting weak but relatively selective inhibition
characteristics of dopamine reuptake (4).
In smoking cessation, BUP does not replace nicotine, but it
is believed to act by increasing dopamine levels in the nucleus
accumbens because dopamine level can be decreased during
cigarette abstinence (5).
After two or three years of prescription for tobacco-use ces-
sation, several articles concerning bupropion toxicity appeared
in the literature (6–8). The clinical toxicity of BUP overdose in-
cluded sinusoidal tachycardia, hypertension, hallucinations,
agitation, seizures and tremors, and sometimes drowsiness.
These side effects might be prolonged with the sustained-re-
lease forms of bupropion (Zyban, Wellbutrin SR®) (9).
Cardiac manifestations are uncommon (except for tachy-
cardia); nevertheless, overdose with more than 1.5 g has been
associated with disturbance of intraventricular conduction and
prolongation of the QT interval. With massive overdose (10 g
or more), cardiac failure and death can occur in absence of fast
treatment. The rates of 0.01 and 0.11 deaths per 1000 pre-
scriptions, respectively, were reported in Canada and the United
Kingdom. Almost all deaths were related to intentional BUP
overdoses (10).
Very few postmortem toxicological data including BUP have
been published (11–13). The interpretation of blood concen-
trations is complicated by the fact that BUP is unstable in
blood and is extensively metabolized by multiple pathways into
two major and one minor active metabolites, hydroxybupro-
pion (OH-BUP) and the amino-alcohol isomers, threohy-
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drobupropion (T-BUP) and erythrohydrobupropion (E-BUP).
The identification and quantification of these metabolites are
essential to reveal intoxications by BUP (14,15). Figure 1 pre-
sents chemical structures of BUP, OH-BUP, T-BUP, and E-BUP.
The present article describes a liquid chromatog-
raphy–electrospray ionization-tandem mass spectrometry
(LC–ESI-MS–MS) method for the rapid and sensitive identifi-
cation and quantification of BUP and its metabolites in blood
and urine and its application to a fatal case of Zyban overdose.
Case History
A 35-year-old male was found lying in his bed about 72 h after
he died. An empty box of Zyban (30 slow-release tablets of 150
mg of BUP) was near the body. The young man had been fol-
lowing a six-month treatment to stop tobacco use. No other
known medication was involved. No goodbye letter was found
in the room, but he had become increasingly depressed ac-
cording to his family. The incident occurred during a very hot
period in the summer, which led to the partial decomposition
of the body. No autopsy was imposed by legal authorities, so
only femoral whole blood and urine samples were collected
for analysis during the external examination.
Materials and Methods
Chemicals and reagents
BUP, OH-BUP, and T-BUP were kindly provided by Glaxo-
SmithKline (Stevenage, U.K.) as hydrochloride salts. The in-
ternal standard (I.S.), decadeuterated lidocaine, was obtained
from C/D/N Isotopes (Pointe-Claire, QC, Canada). Methanol
and acetonitrile were purchased from Carlo Erba Reagents (Val
de Reuil, France); formic acid (99% min) and ammonium for-
mate were from Sigma (Saint Quentin Fallavier, France); and
methylene chloride, propan-2-ol, and zinc sulfate were from
VWR (Strasbourg, France).
Preparation of standard solutions
BUP, OH-BUP, T-BUP, and I.S. powders were separately dis-
solved in methanol to obtain stock solutions at 1 g/L. Then the
solutions were mixed and appropriately diluted in deionized
water to obtain four pools of working solutions of BUP, OH-BUP,
and T-BUP at 5, 1, 0.5, and 0.1 mg/L, and the I.S. was diluted in
deionized water at 5 mg/L. These standard solutions were
stored at +4°C.
Instrumentation
The chromatographic system consisted of a series 200LC
micro-flow rate, high-pressure gradient pumping system
(Perkin-Elmer Instruments, Les Ulis, France) including a Rheo-
dyne model 7725 injection valve equipped with a 20-µL in-
ternal loop. Two mobile phases previously degassed by nitrogen
were employed. Mobile phase A was ammonium formate buffer
(2mM, pH 4.0). Mobile phase B was a 90:10 (v/v) mixture of ace-
tonitrile and ammonium formate buffer (2mM, pH 4.0). The
flow rate was 50 µL/min. A SymmetryShield RP 18 column
(150 × 1.0-mm i.d., 3.5 µm, Waters, Milford, MA) was used for
compound separation with a gradient of mobile phases A and B
programmed as following: 0–1.0 min, 5% B; 1.0–1.5 min, 5 to
35% B; 5.0–5.5 min, 35 to 40% B; 5.5–7.5 min, 40 to 95% B;
7.5–8.5 min, decrease from 95 to 5% B; and 8.5–12 min,
column equilibration with 5% B.
Detection was carried out with an API 2000 LC–MS–MS
System (Applied Biosystems/MDS Sciex, Concord, ON, Canada)
equipped with a TurboIonSpray ionization source and con-
trolled by Analyst® software. The TurboIonSpray settings were
optimized by infusing, at 5 µL/min, a 1 mg/L solution of the
four compounds (BUP, OH-BUP, T-BUP, and I.S.) prepared in a
30:70 (v/v) mixture of acetonitrile and formate buffer (2mM, pH
4.0). In the positive mode, the optimal settings of the ionization
in the source were ion spray voltage at 5000V and curtain gas
and ion source gas 1 at 40 and 20 units, respectively. The
declustering potential (DP) was optimized for each compound
as shown in Table I.
Sample preparation
Calibration standards at 0, 10, 25, 50, 100, 200, and 500 µg/L
were prepared by spiking 100 µL of drug-free human whole
blood and urine with 10 µL of the I.S. solution prepared at 5
mg/L and the appropriate volumes of the different working so-
lutions.
Table I. Optimized Mass Spectrometric Parameters
Q1 Q3
Mass* Mass DP FP EP CEP CE CXP
Analytes (amu) (amu) (V) (V) (V) (V) (V) (V)
I.S. 246.0 96.2 41.0 360.0 –10.0 12.0 27.0 0.0
OH-BUP 255.9 238.0 11.0 360.0 –6.0 14.0 15.0 4.0
255.9 167.1 16.0 350.0 –6.5 20.0 33.0 0.0
BUP 239.9 166.0 16.0 370.0 –6.5 14.0 25.0 2.0
239.9 184.0 16.0 370.0 -6.0 12.0 17.0 2.0
T-BUP 242.3 168.2 16.0 360.0 –9.5 14.0 23.0 0.0
242.3 186.0 16.0 360.0 –10.5 14.0 15.0 2.0
* Q1 mass, parent ion mass-to-charge ratio; Q2 mass, daughter ion mass-to-charge
ratio; DP, declustering potential (orifice plate); FP, focusing potential (focusing
ring); EP, entrance potential (Q0 less); CEP, cell entrance potential; CE, collision
cell potential; and CXP, cell exit potential.Figure 1. Chemical structures of BUP, OH-BUP, T-BUP, and E-BUP.
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Then 0.5 mL of a 70:30 (v/v) mixture of zinc sulfate saturated
aqueous solution and methanol was added to blood (not to
urine) in order to precipitate blood proteins. Spiked blood and
urine samples were vortex mixed for 10 s and centrifuged at
3000 rpm for 5 min. Supernatants were transferred to 15-mL
glass tubes, added to 2 mL of deionized water, and vortex mixed
for 10 s. Oasis® HLB extraction cartridges were conditioned by
2 mL of methanol and equilibrated by 2 mL of deionized water.
Then supernatants were loaded, and cartridges were succes-
sively washed by 3 mL of deionized water and 3 mL of a 90:10
(v/v) mixture of deionized water and methanol. Cartridges
were dried for 15 min, and washing solutions were eliminated.
Solutes were eluted by 3 mL of a methylene chloride and
propan-2-ol (75:25, v/v) mixture and collected in 10-mL glass
tubes. Eluates were evaporated under nitrogen flux at room
temperature and reconstituted with 50 µL of a 10:90 (v/v) mix-
ture of acetonitrile and formate buffer (2mM, pH 4.0). These
extracts were introduced in 200-µL vials for injection, and 10
µL was injected into our LC–ESI-MS–MS system (16).
Results and Discussion
BUP and its main metabolites were identified by multiple
reactions monitoring (MRM) detection. Table II shows the
mass transitions of each analyte and their retention times.
The “mass transition 1” corresponds to the mass transition
used for the quantification; the “mass transition 2” confirms
the first one.
The particular case of the amino-alcohol isomers, T-BUP
and E-BUP, was studied. Indeed, T-BUP and E-BUP co-elute
(relative retention time: 1.06) and show the same MRM tran-
sitions with equivalent abundances under our LC–ESI-MS–MS
conditions. Moreover, previous pharmacokinetics studies have
shown that E-BUP concentrations in human plasma are very
low and only contribute to a small portion of the overall com-
bination peak (17–22). As a consequence, we decided to analyze
and quantify the main analyte, T-BUP.
Method validation
Calibration curves obtained between 10 and 500 µg/L for
BUP and its two main metabolites, using linear regression
without weighting, gave excellent correlation coefficients (r >
0.993). For all analytes, the limits of detection and quantitation
were 5 and 10 µg/L, respectively.
Extraction recovery was determined by comparing the rep-
resentative peak areas of extracted drug-free blood (or urine)
spiked before extraction, with the peak area of drug-free blood
(or urine) fortified before injection, at the same concentration.
The extraction recoveries were higher than 54.3%, 63.4%, and
60.5%, respectively, for BUP, OH-BUP, and T-BUP. Coefficient of
variability (C.V.) values were determined at 10, 50, 200, and
500 µg/L by replicate analyses (n = 5) of human whole blood and
urine aliquots, either on the same run (intraday) or on separate
days (interday) and proved that the method is precise (intraday
and interday C.V. were lower than 11.9% for BUP, OH-BUP, and
T-BUP). Method validation data have been detailed in Table III.
Matrix ion suppression
Matrix ion suppression effects on the MRM LC–MS–MS sen-




Concentrations Uncertainty Recovery Recovery
Products (µg/L) n* CV (%) Accuracy (%) CV (%) Accuracy (%) (%) (%) CV (%)
BUP 10 5 3.8 4.1 9.8 2.9 23.0 79.3 16.7
50 5 11.0 –7.2 7.6 –2.3 17.2 64.6 11.0
200 5 7.6 1.0 4.0 –8.6 16.0 54.3 7.7
500 5 11.9 16.3 8.5 –9.3 24.8 70.4 11.9
T-BUP 10 5 4.0 1.0 3.7 6.8 14.7 61.2 17.4
50 5 3.2 9.2 5.5 1.5 12.7 70.1 3.1
200 5 3.3 0.7 5.6 2.4 13.8 60.5 3.5
500 5 4.7 3.4 3.3 2.1 8.8 64.5 4.6
OH-BUP 10 5 3.1 –1.1 1.5 3.0 6.2 63.4 6.4
50 5 2.0 4.0 4.3 4.6 13.6 90.0 1.8
200 5 2.2 –5.1 4.5 1.7 10.9 73.0 2.2
500 5 2.2 –1.2 3.7 5.8 13.6 75.9 2.3
* n, number of determinations and CV%, coefficient of variation.
Table II. Mass Transitions, Retention Times, and Relative
Retention Times of I.S., BUP, OH-BUP, and T-BUP
Mass Mass Retention Relative
Transition 1 Transition 2 Time Retention
Analytes (m/z > m/z) (m/z > m/z) (min) Time
I.S. 246.0 > 96.2 – 6.76 –
OH-BUP 255.9 > 238.0 255.9 > 167.1 6.94 1.03
BUP 239.9 > 166.0 239.9 > 184.0 7.14 1.06
T-BUP 242.3 > 168.2 242.3 > 186.0 7.14 1.06
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sitivity were evaluated by the experiment of the post-column
analyte infusion described by Antignac et al. (23). A standard
solution containing BUP, OH-BUP, and T-BUP at 100 µg/L and
I.S. at 500 µg/L in mobile phase was infused post-column via
a T-shaped connector, at 50 µL/min, using an infusion pump.
Ten different blank (no spiked) whole blood and urine samples
were extracted. Ten microliters of extracted bloods and urines
was then injected onto an HPLC column at a 50 µL/min mobile
phase flow by a Perkin Elmer autosampler, and MRM
LC–MS–MS chromatograms were acquired for each analyte. No
significant ion suppression effect was observed because of ma-
trix components present in reconstituted extracts.
Case report
Comprehensive toxicology testing was performed. The qual-
itative drug screen, a combination of fluorescence polarization
immunoassay and gas and liquid chromatography of the blood
and urine, showed the presence of bupropion and its metabo-
lites. No other drugs or ethyl alcohol were found. The results
of the toxicological analysis of our reported fatal case are pre-
sented in Table IV. No BUP was found in the femoral blood, and
OH-BUP and T-BUP were detected and respectively quantified
at 5.8 and 30.4 mg/L after suitable dilutions were made. Figure
2 shows chromatograms of the peripheral blood of our re-
ported fatal case. In urine, BUP and its active metabolites were
detected at very high concentrations: BUP at 42.9 mg/L, OH-
BUP at 100 mg/L, and T-BUP at 617.0 mg/L.
In this case study, bupropion could be responsible for death,
even though there was no BUP in the blood at the time of the
analysis. The femoral blood concentration levels of OH-BUP
and T-BUP, 5.8 and 30.4 mg/L, respectively, seem to be within
the range of lethal concentrations in postmortem blood. Friel
et al. (13) studied three fatal overdoses involving BUP and pre-
sented peripheral blood levels as high as 4.0, 3.4, and 11.5
mg/L, respectively, for BUP, OH-BUP, and T-BUP.
To date, if the symptomatology of intoxication by BUP is
well documented, there are few references to blood concen-
trations of BUP and its metabolites in cases of lethal intoxica-
tion by this drug (11,13,15).
In this fatal case, the femoral blood sample was taken about
72 h after the death and refrigerated 4 days before the testing
was done. The analysis did not reveal the presence of BUP.
This result was not surprising insofar as Laizure and DeVane
(14) demonstrated that about 50% of the active compound
BUP was damaged in plasmatic samples stocked at 22°C and
the totality at 37°C, for more than 48 h. Moreover, the authors
also explain that BUP does not degrade into any of the three
metabolites, OH-BUP, E-BUP, and T-BUP. As a consequence
BUP was probably damaged by the hydrolysis of the carbon-ni-
trogen bond of the amino group. The studies of Laizure and
DeVane (14) demonstrated on the other hand the very good sta-
bility of these three metabolites. Therefore, we can suppose
that the blood concentrations of OH-BUP (5.8 mg/L) and T-BUP
(30.4 mg/L) determined with samples taken three days after the
death are in accordance with antemortem concentrations,
without taking redistribution postmortem into account. On
this assumption, these concentrations are quite comparable
with a lethal overdose observed by other authors: from 1.7 to
5.0 mg/L for OH-BUP and from 4.6 to 17.8 mg/L for T-BUP
(11,13,15).
In blood, lethal concentrations are much higher than ther-
apeutic concentrations (therapeutic concentrations of BUP in
blood ranged between 25 and 100 µg/L) (3). Considering toxi-
cological findings (lethal blood concentrations of metabolites)
and the features of BUP toxicity symptoms in case of overdose
described by Jepsen et al. (9) (cardiovascular with prolonged
QRS and QT, and neurological with seizure and coma), the
death could be the result of BUP toxic effects, although the
death circumstances were unknown.
Conclusions
We developed a specific and sensitive LC–ESI-MS–MS
method for the identification and the quantification of BUP and
its main metabolites in blood and urine. This method was val-
idated from 10 to 500 µg/L for each analyte. Applied to a
forensic case of a suicide with BUP, the method revealed lethal
Table IV. Concentrations of BUP and its Metabolites
Obtained after Suitable Dilution of the Postmortem
Samples of the Reported Fatal Case
Sample BUP (mg/L) OH-BUP (mg/L) T-BUP (mg/L)
Femoral blood Not detected 5.8 30.4
Urine 42.9 100 617
Figure 2. Chromatograms of the peripheral blood (dilution: 1:100) of our
reported fatal case spiked with I.S.: full chromatogram (A); I.S. mass
transition (B); OH-BUP mass transitions 1 and 2 (C, D); BUP mass tran-
sitions 1 and 2 (E, F); and T/E-BUP mass transitions 1 and 2 (G, H).
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concentrations in blood (only metabolites were found because
BUP is unstable) and urine. This sensitive method seems to be
able to monitor bupropion in tobacco substitution, as well as
to reveal intoxications by bupropion in forensic cases when
Zyban is implicated (plasmatic therapeutic concentrations of
BUP, OH-BUP, and T-BUP range between 20 and 100 µg/L, 94
and 486 µg/L, and 27 and 213 µg/L, respectively) (3,24). In this
forensic case, BUP had disappeared from blood but was identi-
fied in urine at very high concentration, and OH-BUP and T-
BUP were detected and quantified in blood and urine at lethal
or at least very high concentrations. BUP seemed to be re-
sponsible of death because no other drug neither drug of abuse
was revealed by general blood and urine screening.
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